Q1 Earnings Forecast for CVKD Issued By Noble Financial

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Analysts at Noble Financial issued their Q1 2027 earnings estimates for shares of Cadrenal Therapeutics in a research report issued on Monday, August 17th. Noble Financial analyst R. Leboyer expects that the company will earn ($0.88) per share for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($4.01) per share. Noble Financial also issued estimates for Cadrenal Therapeutics’ Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.93) EPS and Q4 2027 earnings at ($0.92) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its earnings results on Thursday, August 13th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.28.

Other analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Stock Down 5.9%

Shares of CVKD opened at $1.76 on Tuesday. Cadrenal Therapeutics has a twelve month low of $1.71 and a twelve month high of $14.64. The company has a market capitalization of $6.02 million, a P/E ratio of -0.36 and a beta of 1.84. The firm has a 50 day moving average of $2.66 and a 200 day moving average of $4.76.

Insiders Place Their Bets

In other news, CEO Quang X. Pham sold 9,029 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.05, for a total value of $27,538.45. Following the transaction, the chief executive officer directly owned 105,989 shares in the company, valued at $323,266.45. This trade represents a 7.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 87,726 shares of company stock worth $333,575. 14.59% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CVKD. DRW Securities LLC purchased a new stake in shares of Cadrenal Therapeutics during the 4th quarter valued at about $171,000. Citadel Advisors LLC bought a new stake in Cadrenal Therapeutics during the third quarter valued at approximately $274,000. Geode Capital Management LLC increased its holdings in Cadrenal Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Cadrenal Therapeutics in the third quarter worth approximately $103,000. Institutional investors own 7.92% of the company’s stock.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.